替加环素对广泛耐药性鲍曼不动杆菌感染清除效果分析被引量：1

在线阅读下载PDF

导出

摘要目的:分析替加环素对广泛耐药性鲍曼不动杆菌感染患者的细菌清除效果。方法:选取2015年1月~2016年12月我院收治的广泛耐药性鲍曼不动杆菌感染患者60例,随机分成A组和B组,每组30例。A组采用头孢哌酮-舒巴坦进行治疗,B组在A组的基础上加用替加环素进行治疗,比较两组的治疗效果、细菌清除率及炎性指标。结果:B组的有效率为80.00%,优于A组的53.33%,差异有统计学意义,P<0.05;B组的细菌清除率为60.00%,优于A组的33.33%,差异有统计学意义,P<0.05;治疗后,B组的降钙素原和白细胞水平下降幅度明显大于A组,差异有统计学意义,P<0.05。结论:联合应用替加环素治疗泛耐药性鲍曼不动杆菌感染患者,能提高细菌清除率,改善患者的炎性指标。

作者朱健武徐传藩袁科

机构地区广东省珠海市第二人民医院呼吸内科

出处《实用中西医结合临床》 2017年第6期14-16,共3页 Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine

关键词鲍曼不动杆菌感染替加环素细菌

分类号 R515 [医药卫生—内科学]

引文网络
相关文献

参考文献6

1张鹏,李淑芸,杜云波,李超梁,陈炎堂.替加环素治疗耐碳青霉烯鲍曼不动杆菌感染的临床疗效[J].中国感染控制杂志,2016,15(6):380-383. 被引量：20
2《抗菌药物应用指导原则》选登[J].新医学,2005,36(1):48-49. 被引量：2
3王凯歌,谭芬,彭红,陈平.替加环素治疗泛耐药鲍曼不动杆菌医院获得性肺炎的临床疗效及不良反应[J].中国感染控制杂志,2016,15(2):97-101. 被引量：30
4高金丹,方强,苏群.替加环素治疗多重或泛耐药鲍曼不动杆菌引起的重症肺炎的疗效评价[J].中国抗生素杂志,2015,40(8):621-625. 被引量：69
5龙鼎,喻莉,杨军辉.替加环素联合头孢哌酮舒巴坦钠治疗广泛耐药鲍曼不动杆菌老年肺部感染疗效观察[J].中华实用诊断与治疗杂志,2016,30(5):512-514. 被引量：52
6臧会玲,王生池,程慧,王立忠,梁少卿.替加环素联合头孢哌酮/舒巴坦治疗多重耐药及泛耐药鲍曼不动杆菌临床效果分析[J].中国综合临床,2016,32(1). 被引量：29

二级参考文献49

1卫生部办公厅.多重耐药菌医院感染预防与控制技术指南(试行).2011-01-17.
2American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
3Zavascki A P, Carvalhaes C G, Picoo R C, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii:resistance mechanisms and implications for therapy[J]. Expert Rev Anti Infect Ther, 2010, 8(1): 71-93.
4Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al. Tigecycline for the treatment of multidrug- resistant(including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(1): 45-55.
5Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baurnannii and treated with tigecycline alone or in combination therapy[J]. Infection, 201 I, 39(6): 515-518.
6Gallagher J C, Rouse H M. Tigecycline for the treatment of Acinetobaeter infections: a case series[J]. Ann Pharmacother, 2008, 42(9): 1188- 1194.
7Gordon N C, Wareham D W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline[J]. J Antimicrobial Chemother, 2009, 63(4): 775-780.
8Shin J A, Chang Y S, Kim H J, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med J, 2012, 53(5): 974-984.
9De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Criti Care, 2014, 18(3): R90.
10American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilatorassociated, and healthcareassociated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4): 388 -416.